The art of the possible in approaching efficacy trials for COVID19 convalescent plasma

COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Farrugia, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836915/
https://www.ncbi.nlm.nih.gov/pubmed/33130197
http://dx.doi.org/10.1016/j.ijid.2020.10.074
_version_ 1783642848863715328
author Focosi, Daniele
Farrugia, Albert
author_facet Focosi, Daniele
Farrugia, Albert
author_sort Focosi, Daniele
collection PubMed
description COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide suggestions for the next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.
format Online
Article
Text
id pubmed-7836915
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-78369152021-01-26 The art of the possible in approaching efficacy trials for COVID19 convalescent plasma Focosi, Daniele Farrugia, Albert Int J Infect Dis Perspective COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide suggestions for the next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-01 2020-10-30 /pmc/articles/PMC7836915/ /pubmed/33130197 http://dx.doi.org/10.1016/j.ijid.2020.10.074 Text en © 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Perspective
Focosi, Daniele
Farrugia, Albert
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
title The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
title_full The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
title_fullStr The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
title_full_unstemmed The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
title_short The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
title_sort art of the possible in approaching efficacy trials for covid19 convalescent plasma
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836915/
https://www.ncbi.nlm.nih.gov/pubmed/33130197
http://dx.doi.org/10.1016/j.ijid.2020.10.074
work_keys_str_mv AT focosidaniele theartofthepossibleinapproachingefficacytrialsforcovid19convalescentplasma
AT farrugiaalbert theartofthepossibleinapproachingefficacytrialsforcovid19convalescentplasma
AT focosidaniele artofthepossibleinapproachingefficacytrialsforcovid19convalescentplasma
AT farrugiaalbert artofthepossibleinapproachingefficacytrialsforcovid19convalescentplasma

Ejemplares similares